Non-formulary lorlatinib (Lorbrena) will be covered on the prescription drug benefit when the following criteria are met:

● Prescribed by an oncologist or hematologist

AND

● Diagnosis of anaplastic lymphoma kinase (ALK)- positive, metastatic, non-small cell lung cancer

AND

● Patient progressed on first-line crizotinib and at least one other ALK inhibitor (alectinib, ceritinib, or brigatinib)

OR

● Patient progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease